Expertos Invitados





ASPECTOS GENETICOS DA SUSCETIBILIDADE DO HOSPEDEIRO A HANSENIASE

(especial para SIIC © Derechos reservados)
Esta revisão oferece uma síntese dos últimos avanços obtidos na área a partir de estudos genéticos epidemiológicos e funcionais.
tavoramira9_91410.jpg Autor:
Marcelo Távora mira
Columnista Experto de SIIC

Institución:
Pontifïcia Universidade Católica do Paraná

Artículos publicados por Marcelo Távora mira
Coautores
Angela Schneider Francio* Renata Helena Monteiro Sindeaux** Vinicius Medeiros Fava*** Geovana Brotto Ramos**** Vanessa Santos Sotomaior***** 
Candidata a mestrado, Pontifïcia Universidade Católica do Paraná, Curitiba, Brasil*
Especialista, candidata a doutorado, Pontifïcia Universidade Católica do Paraná, Curitiba, Brasil**
Graduado, candidato a doutorado, Pontifïcia Universidade Católica do Paraná, Curitiba, Brasil***
Graduada, candidata a mestrado, Pontifïcia Universidade Católica do Paraná, Curitiba, Brasil****
Doutora, Pontifïcia Universidade Católica do Paraná, Curitiba, Brasil*****
Recepción del artículo
10 de Agosto, 2010 		Aprobación
20 de Octubre, 2010
Primera edición
24 de Noviembre, 2010 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ASPECTOS GENETICOS DA SUSCETIBILIDADE DO HOSPEDEIRO A HANSENIASE

Resumen
Hanseníase é uma doença infecciosa crônica que ainda afeta aproximadamente 215 000 pessoas em todo o mundo. Observações clínicas e epidemiológicas sugerem que apenas uma pequena parcela de indivíduos expostos ao Mycobacterium leprae desenvolvem a doença. Hoje, sabe-se que mecanismos de controle da suscetibilidade a fenótipos da doença dependem, em grande parte, das características genéticas do hospedeiro. Esta revisão oferece uma síntese dos últimos avanços obtidos na área a partir de estudos genéticos epidemiológicos e funcionais.

Palabras clave
hanseníase, formas clínicas, estados reacionais, estudos funcionais, genética do hospedeiro, polimorfismos


Artículo completo
(castellano)
Extensión:  +/-6.78 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Host Genetics and Susceptibility to Leprosy

Abstract
Leprosy is a chronicle infectious disease that still affects approximately 215 000 individuals worldwide. Clinical and epidemiological observations suggest that only a small proportion of the population exposed to Mycobacterium leprae develop the disease. Today, it is known that mechanisms controlling susceptibility to leprosy phenotypes strongly depend on the genetic background of the host. This review summarizes the latest advances in the field, obtained from genetic epidemiology and functional studies.

Key words
leprosy, leprosy clinical forms, leprosy reactions, functional studies, host genetics, polymorphisms

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Dermatología, Infectología
Relacionadas: Anatomía Patológica, Atención Primaria, Diagnóstico por Laboratorio, Epidemiología, Genética Humana, Medicina Interna, Salud Pública



Comprar este artículo
Extensión: 6.78 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Marcelo Távora Mira, Pontifïcia Universidade Católica do Paraná, 80.215-901, Rua Imaculada Conceição, 1155, PPGCS- CCBS, Curitiba, Brasil
Bibliografía del artículo


1. Leprosy fact sheet (revised in February 2010). Wkly Epidemiol Rec 85(6):46-8, 2009.
2. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34(3):255-73, 1966.
3. Hansen GA. Spedalskhedens Arsager. Norsk Magazin for Laegevidenskaben 1874 1955:76-9.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 19(2):338-81, 2006.
5. Mira MT. Genetic host resistance and susceptibility to leprosy. Microbes Infect 8(4):1124-31, 2006.
6. Abel L, Demenais F. Detection of major genes for susceptibility to leprosy and its subtypes in a Caribbean island: Desirade island. Am J Hum Genet 42(2):256-66, 1988.
7. Lazaro FP, Werneck RI, Mackert CC, Cobat A, Prevedello FC, Pimentel RP, et al. A major gene controls leprosy susceptibility in a hyperendemic isolated population from north of Brazil. J Infect Dis 201(10):1598-605.
8. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D receptor genotype with leprosy type. J Infect Dis 179(1):187-91, 1999.
9. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans. Am J Trop Med Hyg 65(6):733-5, 2001.
10. Rajalingam R, Singal DP, Mehra NK. Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Tissue Antigens 49(2):168-72, 1997.
11. Moraes MO, Pacheco AG, Schonkeren JJ, Vanderborght PR, Nery JA, Santos AR, et al. Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun 5(7):592-5, 2004.
12. Vanderborght PR, Pacheco AG, Moraes ME, Antoni G, Romero M, Verville A, et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun 8(4):320-4, 2007.
13. Siddiqui MR, Meisner S, Tosh K, Balakrishnan K, Ghei S, Fisher SE, et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat Genet 27(4):439-41, 2001.
14. Alter A, De Leseleuc L, Van Thuc N, Thai VH, Huong NT, Ba NN, et al. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 127(3):337-48.
15. Mira MT, Alcais A, Van Thuc N, Thai VH, Huong NT, Ba NN, et al. Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. Nat Genet 33(3):412-5, 2003.
16. Mira MT, Alcais A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427(6975):636-40, 2004.
17. Alcais A, Alter A, Antoni G, Orlova M, Nguyen VT, Singh M, et al. Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nat Genet Apr;39(4):517-22, 2007.
18. Wong SH, Hill AV, Vannberg FO. Genomewide association study of leprosy. N Engl J Med 362(15):1446-7; author reply 7-8.
19. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 361(27):2666-8, 2009.
20. Britton WJ, Lockwood DN. Leprosy. Lancet 10;363(9416):1209-19, 2004.
21. Smith WC, Nicholls PG, Das L, Barkataki P, Suneetha S, Suneetha L, et al. Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study. PLoS Negl Trop Dis 3(8):e500, 2009.
22. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clinical Infectious Diseases 44(1):33-40, 2007.
23. Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. Anais Brasileiro de Dermatologia 83(1):75-82, 2008.
24. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 144(1):175-81, 2001.
25. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 19(2):338-81, 2006.
26. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. International Journal of Leprosy and others Mycobacteium Diseases 34(3):255-73, 1966.
27. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 74(5):868-79, 2006.
28. Vasselon T, Detmers PA. Toll receptors: a central element in innate immune responses. Infect Immun 70(3):1033-41, 2002.
29. Bochud PY, Hawn TR, Siddiqui MR, Saunderson P, Britton S, Abraham I, et al. Toll like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. The Journal of Infectious Diseases 197(2):253-61, 2008.
30. Misch EA, Macdonald M, Ranjit C, Sapkota BR, Wells RD, Siddiqui MR, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2(5):e231, 2008.
31. Schuring RP, Hamann L, Faber WR, Pahan D, Richardus JH, Schumann RR, et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 199(12):1816-9, 2009.
32. Berrington WR, Macdonald M, Khadge S, Sapkota BR, Janer M, Hagge DA, et al. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 201(9):1422-35, 2010.
33. Fine PE. Leprosy: what is being "eliminated"? Bull World Health Organ 85(1):2, 2007.
34. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, et al. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 50(5):541-9, 1999.
35. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, et al. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis 9:75, 2009.
36. Malhotra D, Darvishi K, Sood S, Sharma S, Grover C, Relhan V, et al. IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet 118(2):295-300, 2005.
37. Pereira AC, Brito de Souza VN, Cardoso CC, Dias Baptista IM, Parelli FP, Venturini J, et al. Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility. Genes Immun 10(2):174-80, 2009.
38. Shaw MA, Donaldson IJ, Collins A, Peacock CS, Lins-Lainson Z, Shaw JJ, et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun 2(4):196-204, 2001.
39. Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira LM, Cabello PH, et al. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis 186(11):1687-91, 2002.
40. Franceschi DS, Mazini PS, Rudnick CC, Sell AM, Tsuneto LT, Ribas ML, et al. Influence of TNF and IL10 gene polymorphisms in the immunopathogenesis of leprosy in the south of Brazil. Int J Infect Dis 13(4):493-8, 2009.
41. Moraes MO, Duppre NC, Suffys PN, Santos AR, Almeida AS, Nery JA, et al. Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics 53(1):45-7, 2001.
42. Vejbaesya S, Mahaisavariya P, Luangtrakool P, Sermduangprateep C. TNF alpha and NRAMP1 polymorphisms in leprosy. J Med Assoc Thai 90(6):1188-92, 2007.
43. Moura DF, Teles RM, Ribeiro-Carvalho MM, Teles RB, Santos IM, Ferreira H, et al. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br J Dermatol 157(2):273-83, 2007.
44. Hagge DA, Saunders BM, Ebenezer GJ, Ray NA, Marks VT, Britton WJ, et al. Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy. Am J Pathol 174(4):1379-89, 2009.
45. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183(4):1461-72, 1996.
46. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 193(2):239-46, 2001.
47. Le Cabec V, Emorine LJ, Toesca I, Cougoule C, Maridonneau-Parini I. The human macrophage mannose receptor is not a professional phagocytic receptor. J Leukoc Biol 77(6):934-43, 2005.
48. Largent BL, Walton KM, Hoppe CA, Lee YC, Schnaar RL. Carbohydrate-specific adhesion of alveolar macrophages to mannose-derivatized surfaces. J Biol Chem 259(3):1764-9, 1984.
49. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97(24):13354-9, 2000.
50. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25(3):302-5, 2000.
51. Marin I, Ferrus A. Comparative genomics of the RBR family, including the Parkinson's disease-related gene parkin and the genes of the ariadne subfamily. Mol Biol Evol 19(12):2039-50, 2002.
52. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605-8, 1998.
53. Moore DJ. Parkin: a multifaceted ubiquitin ligase. Biochem Soc Trans 34(Pt 5):749-53, 2006.
54. Robinson PA, Ardley HC. Ubiquitin-protein ligases. J Cell Sci 117(Pt 22):5191-4, 2004.
55. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279(18):18614-22, 2004.
56. Yang H, Zhou HY, Li B, Niu GZ, Chen SD. Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells. J Neuroimmune Pharmacol 2(3):276-83, 2007.
57. Fulco TO, Lopes UG, Sarno EN, Sampaio EP, Saliba AM. The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion. Immunol Lett 110(1):82-5, 2007.
58. Ali S, Vollaard AM, Widjaja S, Surjadi C, Van de Vosse E, Van Dissel JT. PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin Exp Immunol 144(3):425-31, 2006.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008